

Ivan Borbath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1243798/publications.pdf>

Version: 2024-02-01

62
papers

20,019
citations

185998

28
h-index

128067

60
g-index

63
all docs

63
docs citations

63
times ranked

21290
citing authors

#	ARTICLE	IF	CITATIONS
1	Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390.	13.9	12,004
2	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2011, 364, 501-513.	13.9	2,216
3	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	5.1	1,816
4	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1844.	3.8	801
5	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
6	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 55-63.	5.1	522
7	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues. <i>Neuroendocrinology</i> , 2017, 105, 295-309.	1.2	229
8	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	3.7	205
9	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification. <i>Neuroendocrinology</i> , 2017, 105, 196-200.	1.2	178
10	An update on treatment options for pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987556.	1.4	144
11	Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial. <i>Gastroenterology</i> , 2021, 161, 899-909.e5.	0.6	99
12	Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. <i>European Journal of Cancer</i> , 2017, 79, 158-165.	1.3	84
13	The Place of Whole-Body PET FDG for the Diagnosis of Distant Recurrence of Breast Cancer. <i>Molecular Imaging and Biology</i> , 2000, 3, 45-49.	0.3	80
14	Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 591-598.	3.3	71
15	Preoperative assessment of pancreatic tumors using magnetic resonance imaging, endoscopic ultrasonography, positron emission tomography and laparoscopy. <i>Pancreatology</i> , 2005, 5, 553-561.	0.5	65
16	Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). <i>Neuroendocrinology</i> , 2019, 108, 54-62.	1.2	62
17	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	1.1	62
18	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. <i>Oncotarget</i> , 2016, 7, 72622-72633.	0.8	60

#	ARTICLE	IF	CITATIONS
19	Diagnostic and Therapeutic Roles of Endoscopic Ultrasound in Pediatric Pancreaticobiliary Disorders. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2015, 61, 238-247.	0.9	58
20	Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1253-1259.	0.8	55
21	Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. <i>Transplant International</i> , 2010, 23, 668-678.	0.8	52
22	Accuracy of Pancreatic Neuroendocrine Tumour Grading by Endoscopic Ultrasound-Guided Fine Needle Aspiration: Analysis of a Large Cohort and Perspectives for Improvement. <i>Neuroendocrinology</i> , 2018, 106, 158-166.	1.2	52
23	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , 2018, 107, 237-245.	1.2	37
24	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	3.7	36
25	Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. <i>European Journal of Cancer</i> , 2021, 157, 403-414.	1.3	33
26	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2547-2554.	3.2	32
27	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 14408-14415.	0.8	30
28	Safety and QOL in Patients with Advanced NET in a Phase 3b Expanded Access Study of Everolimus. <i>Targeted Oncology</i> , 2016, 11, 667-675.	1.7	28
29	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw277.	3.0	28
30	<i>Kras</i> and <i>Lkb1</i> mutations synergistically induce intraductal papillary mucinous neoplasm derived from pancreatic duct cells. <i>Gut</i> , 2020, 69, 704-714.	6.1	27
31	Impact of Intraoperative Pancreatoscopy with Intraductal Biopsies on Surgical Management of Intraductal Papillary Mucinous Neoplasm of the Pancreas. <i>Journal of the American College of Surgeons</i> , 2015, 221, 982-987.	0.2	25
32	Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. <i>British Journal of Cancer</i> , 2018, 118, 181-188.	2.9	23
33	Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. <i>Chemico-Biological Interactions</i> , 2010, 183, 238-248.	1.7	20
34	Endoscopic ultrasound-guided radiofrequency ablation: An effective and safe alternative for the treatment of benign insulinoma. <i>Annales D'Endocrinologie</i> , 2020, 81, 567-571.	0.6	20
35	Use of 5-[⁷⁶ Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 19-27.	3.3	19
36	Liver and Pancreas: Do Similar Embryonic Development and Tissue Organization Lead to Similar Mechanisms of Tumorigenesis?. <i>Gene Expression</i> , 2018, 18, 149-155.	0.5	19

#	ARTICLE	IF	CITATIONS
37	The Role of PPAR in Hepatocellular Carcinoma. PPAR Research, 2008, 2008, 1-4.	1.1	18
38	131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2005, 17, 905-910.	0.8	17
39	Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. Future Oncology, 2019, 15, 1219-1230.	1.1	17
40	Risk of advanced lesions in patients with branch-duct IPMN and relative indications for surgery according to European evidence-based guidelines. Digestive and Liver Disease, 2019, 51, 882-886.	0.4	14
41	Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. Cancer Science, 2007, 98, 1831-1839.	1.7	12
42	Impact of needle-based confocal laser endomicroscopy on the therapeutic management of single pancreatic cystic lesions. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 2532-2540.	1.3	12
43	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. Journal of Neuroendocrinology, 2022, 34, e13105.	1.2	12
44	The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms. European Journal of Cancer, 2022, 168, 80-90.	1.3	12
45	Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): Protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer, 2013, 13, 190.	1.1	11
46	Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.. Journal of Clinical Oncology, 2019, 37, 345-345.	0.8	11
47	Significant impact of transient deterioration of renal function on dosimetry in PRRT. Annals of Nuclear Medicine, 2013, 27, 74-77.	1.2	9
48	Prediction of tumor response and patient outcome after radioembolization of hepatocellular carcinoma using 90Y-PET-computed tomography dosimetry. Nuclear Medicine Communications, 2021, 42, 747-754.	0.5	9
49	Preoperative gemcitabine-nab-paclitaxel (G-NP) for (borderline) resectable (BLR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC): Feasibility results and early response monitoring by Diffusion-Weighted (DW) MR.. Journal of Clinical Oncology, 2016, 34, 4116-4116.	0.8	9
50	Ras inhibition in hepatocarcinoma by <i>S-trans-farnesylthiosalicylic acid</i> : Association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis. Molecular Carcinogenesis, 2012, 51, 816-825.	1.3	7
51	The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2017, 35, 380-380.	0.8	6
52	Tetrahydro Iso-Alpha Acids and Hexahydro Iso-Alpha Acids from Hops Inhibit Proliferation of Human Hepatocarcinoma Cell Lines and Reduce Diethylnitrosamine Induced Liver Tumor Formation in Rats. Nutrition and Cancer, 2015, 67, 748-760.	0.9	5
53	Sorafenib Reduced Significantly Hepatopulmonary Shunt in a Large Hepatocellular Carcinoma. Clinical Nuclear Medicine, 2019, 44, 70-71.	0.7	5
54	Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 european patientsâ€™ The ENETS registry.. Journal of Clinical Oncology, 2018, 36, 4095-4095.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2017, 49, 568-571.	0.4	3
56	How to treat intestinal obstruction due to malignant recurrence after Whipple's resection for pancreatic head cancer: Description of 2 new endoscopic techniques. <i>World Journal of Gastroenterology</i> , 2017, 23, 6181-6186.	1.4	3
57	To the editor:. <i>Hepatology</i> , 2003, 37, 477-478.	3.6	2
58	Chemotherapy for pancreatic cancer: the rise of multidrug regimens. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 659-660.	3.7	2
59	Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. <i>Current Oncology</i> , 2022, 29, 2422-2434.	0.9	2
60	External validation of a prognostic score in patients (pts) with high-grade gastrointestinal neuroendocrine carcinomas (GI-NECs).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4089-4089.	0.8	0
61	REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4148-TPS4148.	0.8	0
62	Granuloma formation within perihepatic lymphadenopathy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101504.	0.7	0